by Joe Bunting | May 6, 2022 | Independent Research
We hear of the imminent death of the 60:40 portfolio as interest rates normalise. At Tellsons we believe that the recalibration of asset prices in recent months – the worst start to a year for both stocks and bonds in generations is a welcome ‘burning of the...
by Christoph Wiedebach | Apr 22, 2022 | Independent Research
This week saw two of the Top Ten holdings in the EF Tellsons Endeavour Fund report first quarter earnings – Bank of America (2.3%) and Charles Schwab (2.2%). Here we take a look at their results and prospects for each going forward: Bank of AmericaOne of our top...
by Joe Bunting | Mar 14, 2022 | Independent Research
The humanitarian tragedy of Russia’s invasion of the Ukraine has descended like a pall over the world, and it is clear that defenceless civilians and the truth are as always the first victims of war. Reading between the claims and counterclaims and peering...
by Joe Bunting | Feb 12, 2022 | Independent Research
AstraZeneca reassured markets on Thursday with a solid set of results that reiterated its excellent growth potential. Over the past year, the company has battled negativity around their Covid vaccine, pricing pressures in China and their £29 billion acquisition of...
by Joe Bunting | Jan 23, 2022 | Independent Research
I wrote in November about the likelihood that Unilever would use acquisitions to boost its growth. So the weekend news that the company had made three unsuccessful bids for GlaxoSmithKline’s consumer health business was not surprising, but the scale of ambition in...
by Tellsons | Jan 14, 2022 | Independent Research
Fund Managers: Joe Bunting, Christoph Wiedebach, Cranley Macfarlane MARKET BACKDROP: The fourth quarter saw markets struggle to balance the inflationary pressures of ongoing supply chain bottlenecks as the new Covid Omicron wave swept rapidly across the globe with...